What is the new ICS inhaler? The rise of dual-action and smart devices
•
4 min read
In January 2023, the FDA approved Airsupra (albuterol/budesonide), the first and only dual-action rescue inhaler to combine a short-acting beta-agonist (SABA) with an inhaled corticosteroid (ICS). This development marks a significant shift in respiratory care, offering a new approach to managing asthma attacks and underlying inflammation simultaneously.
